GeneQuine is focused on developing gene therapy for the treatment of musculoskeletal disorders. The company’s management and scientists are biopharma and gene therapy experts, driven by the potential that gene therapy holds to revolutionize the treatment of chronic, musculoskeletal disorders. GeneQuine’s management is supported by a strong advisory board with science, pharma and venture capital backgrounds.
Management
Kilian Guse, PhD
CEO, Co-Founder
Dr. Guse is the CEO and co-founder of GeneQuine. He has more than 15 years experience in gene therapy research and development and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic.
Stanislav Plutizki, PhD
COO, Co-Founder
Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany, where he was responsible for medical and scientific management of a large product portfolio.
Advisory Board
Bernhard J. Kirschbaum, PhD
Chairman of the Board
Dr. Kirschbaum is a board member of several biotech companies and has 20 years of experience in R&D of global international pharma companies at Hoechst Maron Roussel, Aventis, Sanofi-Aventis, and Merck Serono, and was in his last position Executive Vice President, Global Research & Early Development and member of the board at Merck Serono.
Amel Tounsi, PhD
Dr. Tounsi is a scientist with immunology and cellular biology background, experienced in cell therapy development from R&D to clinical phase, business development and company Development strategy. Continuous learning and training on the managerial and entrepreneurial aspect of the biotech industry is her drive.
Martin Pfister, PhD
Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald, Germany, and New York University, USA, and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene.
Ronald J. Ellis, Jr., DO
Ron Ellis brings over 20 years of healthcare experience in medicine, clinical research, equity research and institutional investing. Dr. Ellis is currently Senior Vice President of Corporate Strategy & Business Development at Pacira BioSciences, Inc., where he leads the company’s efforts in strategy, licensing and acquisition.
Peter Johann, PhD
Dr. Johann is the founder, Chairman and CEO of Lumendi Ltd., an innovative medtech company focusing on devices enabling/improving endoluminal gastrointestinal interventions. He also is a Managing General Partner of NGN Capital, a healthcare venture capital investor. Dr. Johann had several successful IPOs and M&A transactions in his investment portfolio.
Gencer Sahin
Observer
Gencer Sahin is Head of Investments at the venture capital fund Innovationsstarter Fonds Hamburg GmbH, Hamburg, Germany. He studied industrial engineering, has several years of experience in consulting, and has been active in the start-up scene since 2012.
Scientific Advisory Board
Yves Henrotin, Prof.
Clinical and Scientific Advisor
Professor of Pathology, Physical Therapy and Rehabilitation and Director of the Bone and Cartilage Research Unit at the University of Liège, Belgium; President of Osteoarthritis Foundation.
Collaborations
Baylor College of Medicine
Baylor College of Medicine (BCM), located in Houston, Texas, USA is one of the leading medical schools and biomedical research institutes in the country.
Flexion Therapeutics, Inc.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis.
Grant Support
EU, European Union - European Regional Development Fund (ERDF)
GeneQuine‘s project for the development of a gene therapy for intervertebral disc degeneration (GQ-401) is supported by a grant from the German state of Brandenburg (ProFIT Brandeburg), co-financed by the European Regional Development Fund (ERDF) by the European Union.